Recently, Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) showcased its series of innovative pipelines at the 43rd Annual J.P. Morgan Healthcare Conference. Xia Yuanfeng, Executive Director of Chemical and Biological Affairs of GenSci, presented the latest pipeline outcomes at this conference. 

The innovative pipelines of GenSci shown at this conference cover key disease areas such as oncology, immunology, endocrinology, metabolism, and several rare disease subfields, which includes potential First-in-Class (FIC) and Best-in-Class (BIC) innovative drugs. In the oncology treatment portfolio, several BsADCs and small molecule drugs have demonstrated significant Best-in-Class potential in preclinical studies.

GenSci continues to invest in the development of innovative drugs. In the field of metabolic endocrinology, the NK3R inhibitor GS1-144 has received FDA approval for Phase II clinical trials and was approved by the NMPA in 2023. If launched, it will provide a non-hormonal oral treatment option for patients with menopausal vasomotor symptoms. Additionally, GenSci has launched innovative pipelines targeting rare diseases such as cystic fibrosis (CFTR mRNA), phenylketonuria (small molecule), and organic acidemia (PANK1/3 agonist), aiming to provide more treatment options for rare disease patients worldwide.

Mr. Xia was engaging in discussions with the attendees

Mr. Xia extended that the company is eager to establish strategic partnerships with more multinational corporations and leading pharmaceutical companies to jointly promote innovative achievements to the global market, ultimately benefiting patients worldwide.